Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$132.43 USD

132.43
322,778

+3.19 (2.47%)

Updated Oct 14, 2024 04:00 PM ET

After-Market: $132.54 +0.11 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Veradigm (MDRX) & MedAllies Partner for Better Care Decisions

Veradigm's (MDRX) partnership with MedAllies is likely to gain access to a wider range of patient data and drive better treatment decisions.

Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales

Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.

QIAGEN (QGEN) Gains From New Alliances Amid FX Headwind

QIAGEN (QGEN) is progressing well with its testing menu expansion strategy, which is driving the company's growth.

SenesTech's (SNES) New Partnership to Broaden Evolve's Scope

The collaboration with a global leader in irrigation solutions for sustainable agriculture aligns with SenesTech's (SNES) target to introduce Evolve to a broader audience.

PacBio (PACB) Preliminary Q4 Revenues Boosted by Revio Sales

PacBio's (PACB) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its sequencing systems.

Inspire Medical (INSP) Reports Solid Preliminary Q4 Revenues

Inspire Medical's (INSP) revenue growth in the fourth quarter is likely to have been boosted by improved operating leverage.

DexCom (DXCM) Preliminary Q4 Revenues Ride on Sensor Demand

DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by strong demand for its CGM sensors across the globe. It delivers robust revenue guidance for 2024.

Fresenius Medical (FMS) Divests Businesses to Optimize Portfolio

Fresenius Medical (FMS) streamlines for success with three key divestments in 2023. These divestments are likely to impact operating income by EUR 500 million in the fourth quarter.

Illumina (ILMN) Extends Partnership to Advance Cancer Test

Illumina (ILMN) aims to work with other pharmaceutical industry leaders to enhance and expand the utility of its WGS MRD assay.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

Investors are optimistic about Abbott (ABT) led by solid prospects in the Diagnostic business and raised guidance.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.

Avanos (AVNS) Preliminary Q4 Revenues Dampened by Lower Sales

Avanos' (AVNS) revenue growth in the fourth quarter is likely to have been dampened by lower HA pain relief injection product sales.

Veradigm's (MDRX) Acquires Koha Health to Solidify Market Presence

Veradigm's (MDRX) acquisition of Koha Health will likely enhance its ability to deliver efficient revenue cycle services by incorporating Musculoskeletal Medicine specialty subject matter expertise.

Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Walgreens Boots (WBA) Q1 Earnings Top Estimates, Margins Down

Walgreens Boots' (WBA) comparable pharmacy sales in the fiscal first quarter benefited from higher branded drug inflation and strong execution in pharmacy services.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Investors are optimistic about Myriad Genetics (MYGN) on robust testing volumes and strong solvency position.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Enovis (ENOV) to Strengthen Portfolio Via Its Latest Buyout

Enovis' (ENOV) latest buyout is expected to expand its international scale with a complementary global customer base and product mix and improve efficiency with innovative manufacturing facilities.

Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.

Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Haemonetics (HAE) Up 11% in a Year: Will the Rally Continue?

Investors are optimistic about Haemonetics (HAE) owing to its strategic focus on establishing leading positions in high-growth markets and raised guidance.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

Investors are optimistic about Quest Diagnostics (DGX) on strength in base business and strategic collaborations.

ITGR vs. EW: Which Stock Should Value Investors Buy Now?

ITGR vs. EW: Which Stock Is the Better Value Option?

Cencora (COR) Hits 52-Week High: What's Aiding the Stock?

Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.

Microbot Medical (MBOT) Announces Positive GLP Study Results

Microbot Medical's (MBOT) latest favorable study results are likely to support its IDE submission to the FDA to commence its human clinical study.